

For immediate release:
June 30, 2009

Media contact:
Bridget Forney
Profiles, Inc.
410-243-3790

MEDIA ADVISORY
June 30, 2009

**MIDATLANTIC CARDIOVASCULAR ASSOCIATES IS A TOP
ENROLLER IN NATIONAL SCIENTIFIC TRIAL**

*MADIT-CRT Trial could pave the way for millions of
heart patients to access life-saving treatment*

Baltimore – (June 30, 2009) – The Boston Scientific Corporation recently announced the results of the world's largest randomized medical trial to study the treatment of heart patients using Cardiac Resynchronization Therapy (CRT) as compared to the standard Implantable Cardioverter Defibrillator (ICD) treatment. More than 1,800 patients were enrolled worldwide, and Baltimore-based **MidAtlantic Cardiovascular Associates was the number two enroller in the nation and number three enroller in the world.**

Currently, the use of an ICD is the standard protocol in the treatment of patients who had not qualified for CRT, but who suffer from heart disease. Boston Scientific's trial studied the application of the alternative CRT treatment in this patient population to determine its effectiveness. The results of the trial show that CRT treatment – a type of biventricular pacing, which helps both ventricles contract at the same time - in patients who have heart disease leads to a 29% reduction in death or heart failure. Though these results are preliminary, the results from the study could pave the way for millions of heart patients to access CRT as a life-saving treatment.

Cardiologists of MidAtlantic Cardiovascular Associates are available for comments on the results of Boston Scientific's MADIT-CRT trial and can be accessed by calling Bridget Forney at 410-243-3790.

MidAtlantic Cardiovascular Associates offers full service, responsive heart care through its practice of 58 board-certified cardiologists and cardiac surgeons who deliver comprehensive heart care in its 12 offices and through affiliations with leading regional hospitals.

###